The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
Chronic Lymphocytic Leukemia OS Affected by Low-Burden Mutations
Low-burden mutations, or minor clones, of TP53 abnormalities were once thought to be of little significance but that is no longer the case, according to a recent report.
Study Links Certain Cancers With Increased Risk of Guillain-Barré Syndrome
Not all Guillain-Barré cases are associated with infection, and studies have suggested a link between the rare disorder and certain cancers, including lymphomas.
FDA Accepts sNDA for Zanubrutinib to Treat CLL/SLL
The supplemental new drug application (sNDA) filing includes data from 2 pivotal randomized phase 3 global studies, ALPINE and SEQUOIA, of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The target action date is October 22, 2022.
Overlooked Mutation Contributes to Poor Outcomes in Pediatric Patients With AML
The mutation is more common than expected and associated with poor outcomes, according to researchers from St. Jude Children’s Research Hospital.
Study Examines High-Dose Therapy, ASCT for Rare Type of Non-Hodgkin Lymphoma
Primary central nervous system non-Hodgkin lymphomas are rare extranodal B-cell lymphomas with a poor prognosis and no standard treatment plan.
Test Could Provide Earlier Identification of Relapse in ALL
The new protocol for monitoring acute lymphoblastic leukemia (ALL) is simpler than current techniques and is at least as good as the current gold standard.
Study Evaluates Impact of AE Severity on Health State Utility for CAR T Treatment in LBCL
Health state utilities can be used to examine and compare the cost-effectiveness of the chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphoma (LBCL) as more become available.
CAR T Cells Persist 10 Years After CLL Treatment, Hailed as "Cure"
Researchers, as well as a patient who had chronic lymphocytic leukemia (CLL), hailed the findings as a cure, although more work needs to be done to see if the results persist in a larger group of patients.
Incyte Withdraws FDA Submission for Parsaclisib for FL, MZL, MCL
Incyte has become the latest company to pull an FDA filing following Gilead and Secura Bio, which both voluntarily withdrew therapies that had been granted accelerated approval but hadn’t completed confirmatory studies for full approval.
ASH 2021 Recap: Real-World Evidence
A presentation at the 63rd American Society of Hematology (ASH) annual meeting explored the collection of real-world data.
NCCN Updates Give Zanubrutinib Preference in CLL/SLL
Zanubrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor that has fewer off-target effects and less cardiotoxicity than ibrutinib, a first-generation BTK inhibitor.
Study Identifies Potential Target for Alternative Therapies in Relapsed, Refractory DLBCL
The data published in Scientific Reports are the first to implicate a role for RASGRP4 mutations in B-cell malignancies.
Two-Year OS Doubles for Patients With Philadelphia-Positive Relapsed ALL After HSCT
While acute lymphoblastic leukemia (ALL) was still the primary cause of death, researchers saw a steady increase in 2-year survival from 27.8% to 54.8% even as patient age at the time of relapse after allogeneic hematopoietic stem cell transplantation (HCST) increased.
NCCN Publishes New Guidebook for Patients at Risk of GVHD
Graft-versus-host disease (GVHD) is common, yet it is poorly understood and its symptoms can be difficult to recognize.
Lack of Monitoring Among Older Patients With CML Linked to Poor TKI Adherence
The findings showing that older patients with chronic myeloid leukemia (CML) had poor adherence to tyrosine kinase inhibitors (TKIs) was presented last month during the American Society of Hematology Meeting & Exposition.
Top 5 Most-Read Articles in Leukemia and Lymphoma for 2021
Articles on treating and protecting patients with blood cancers from COVID-19 and the positive results of zanubrutinib to treat leukemia and lymphoma were among the most read of the year.
ASH Posters Evaluate COVID-19 Risk Among Patients With Blood Cancers
Research using data from the ASH Research Collaborative COVID-19 Registry for Hematology identified risk factors for severe infection and mortality for patients with blood cancers who were infected with COVID-19.
Study Shows Need for Earlier Conversations About End-of-Life Care With Patients Who Have High-Risk AML
Third mRNA COVID-19 Vaccine Helps Some Patients With Blood Cancer Produce Antibodies for First Time
There are 2 such vaccines now in use in the United States; the Pfizer-BioNTech vaccine is fully approved for the first 2 doses for those 16 and older, and the Moderna vaccine has an emergency use authorization for those 18 and older.
HIIT May Maintain Health in Older Patients With Treatment-Naïve CLL
High-intensity interval training (HIIT) may maintain health, including immune cell function, for patients with treatment-naïve chronic lymphocytic leukemia (CLL).
Can Earlier Use of Palliative Care Improve End-of-Life Outcomes in AML?
Setting up a palliative care consultation program for patients with acute myeloid leukemia (AML) improved some aspects of care.
Targeted Therapies Offer Attractive Treatment Approach for Elderly/Unfit Patients With CLL
The researchers outlined potential treatment options for this patient population since the emergence and uptake of targeted treatments.
Drug Combination Used in Adults Can Benefit Children With Acute Promyelocytic Leukemia
All-trans retinoic acid and arsenic trioxide used together can let children avoid treatment with convention chemotherapy, which has more adverse effects.
Hospitals Lack Medication Needed for Form of AML, Study Finds
Although acute promyelocytic leukemia is highly treatable in early stages, the medication needed stop hematologic emergencies, all-trans retinoic acid, is often not available, a new study says.
HRQOL Decreased During and Immediately After CAR T-Cell Therapy for DLBCL
Prior to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), patients experienced a decrease in health-related quality of life (HRQOL), which was further impaired during and immediately after CAR T therapy.
Safety Analysis Finds Zanubrutinib’s Toxicity Profile Is Consistent With Other BTK Inhibitors
A safety analysis of 6 trials found zanubrutinib has a toxicity profile consistent wth other Bruton tyrosine kinase (BTK) inhibitors.
Researchers Report Further Analysis of Zanubrutinib Monotherapy for R/R MCL
Fewer Blood Transfusions for Patients With AML Has Humanistic, Economic Benefits
Posters presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting analyzed patient and physician perspectives on blood transfusions in acute myeloid leukemia (AML).
Tazemetostat Yields Fewer Safety Outcomes, Lower AE-Associated Costs vs PI3 Kinase Inhibitors
Two analyses presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting highlighted the safety and cost benefits of tazemetostat compared with phosphoinositide 3 (PI3) kinase inhibitors for patients with follicular lymphoma.
The Cost of Treating AEs Due to CAR T-Cell Therapy Treatment
Two posters presented at AMCP Nexus 2021 analyzed the costs of treating cytokine release syndrome and neurological events, 2 common adverse events (AEs) of chimeric antigen receptor (CAR) T-cell therapy.
2 Clarke Drive Cranbury, NJ 08512